- Home
- HIND vs CELU Comparison
HIND vs CELU Comparison
Compare HIND & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIND | CELU |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 17.3M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HIND | CELU |
|---|---|---|
| Price | $1.78 | $0.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.83 | N/A |
| AVG Volume (30 Days) | 9.8K | ★ 156.0K |
| Earning Date | 11-13-2026 | 10-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.86 | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | $319,714.00 | ★ $26,550,000.00 |
| Revenue This Year | N/A | $165.42 |
| Revenue Next Year | $82.65 | $305.36 |
| P/E Ratio | ★ N/A | $20.14 |
| Revenue Growth | ★ 24.43 | N/A |
| 52 Week Low | $1.62 | $0.56 |
| 52 Week High | $6.33 | $2.55 |
Technical Indicators
Market Signals| Indicator | HIND | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 36.88 |
| Support Level | $1.82 | $0.64 |
| Resistance Level | $2.31 | $0.86 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 46.13 | 21.76 |
Price Performance
Historical ComparisonAbout HIND Vyome Holdings Inc.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
About CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.